Avadel Pharmaceuticals plc

For Q2 2025, Avadel reported net revenue of $68.1 million, up 64% year over year and 30% sequentially, and gross profit of $61.8 million, up 60% year over year and 32% sequentially. Net income was $9.7 million, or $0.10 per diluted share, versus a net loss of $13.8 million, or $0.14 per diluted share, in Q2 2024. Adjusted operating income was $15 million, and cash operating expenses were $46.8 million after $6.1 million of noncash charges. The company ended the quarter with $81.5 million of cash, cash equivalents and marketable securities and generated $15 million of cash in the quarter. Guidance was raised to full-year 2025 revenue of $265 million-$275 million, with Q3 net revenue expected at $71 million-$75 million; management also said Q3 cash operating expenses are expected to be $50 million-$55 million and noncash expenses $6 million-$8 million.

Greg Divis framed the quarter as evidence that the LUMRYZ launch is gaining traction and becoming more efficient, citing stronger patient demand, improved persistency, better reimbursement, and a broadened prescriber base. He stressed that the product is not only taking share in oxybates but also expanding the market by attracting new prescribers, including physicians who had not historically prescribed an oxybate. His tone was upbeat and confident, and he highlighted IH, the low/no-sodium extended-release formulation work, and the antitrust litigation as longer-term value drivers.

Tom McHugh focused on the quarter’s financial leverage and the implications of the updated outlook. He reiterated the key figures: $68.1 million revenue, $61.8 million gross profit, $52.9 million GAAP operating expenses, $46.8 million cash operating expenses, $9.7 million net income, and $81.5 million of quarter-end cash and investments. He said the Q3 guide implies continued durability of the first-half improvements and described the company as having ample runway to fund commercial plans and the IH clinical program.

Analysts pressed on whether the raised guidance was conservative, whether Q2 benefited from seasonal or gross-to-net dynamics, and how many patients started therapy during the quarter. Management said the guide assumes continued gains in patient starts, persistency, reimbursement, and patient mix, and noted that Q1-to-Q2 pricing improved partly due to gross-to-net, though they also credited execution initiatives. Questions on the future mix of switch versus naïve patients drew a response that over half of current patients are switch patients, but growth is coming from both deeper use within existing prescribers and expansion to new prescribers. On orexin competition, management said oxybates remain important and may be complementary to future therapies; on IH, they said the opportunity is to grow the overall market rather than rely only on switching patients from Xywav.